Ventyx Biosciences (NASDAQ:VTYX) Upgraded to Hold at Wall Street Zen

Ventyx Biosciences (NASDAQ:VTYX) was upgraded by investment analysts at Wall Street Zen to a “hold” rating in a report issued on Saturday.

Several other equities analysts have also weighed in on the stock. Lifesci Capital reissued a “market perform” rating and issued a $14.00 price objective on shares of Ventyx Biosciences in a research report on Thursday, January 8th. Wells Fargo & Company reiterated an “equal weight” rating and issued a $14.00 price target on shares of Ventyx Biosciences in a research note on Thursday, January 8th. Canaccord Genuity Group cut shares of Ventyx Biosciences from a “buy” rating to a “hold” rating and lowered their price target for the company from $16.00 to $14.00 in a report on Thursday, January 8th. Piper Sandler downgraded shares of Ventyx Biosciences from an “overweight” rating to a “hold” rating and set a $14.00 price objective for the company. in a research report on Thursday, January 8th. Finally, Oppenheimer cut Ventyx Biosciences from an “outperform” rating to a “market perform” rating in a report on Thursday, January 8th. Eight investment analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Reduce” and a consensus target price of $14.00.

Ventyx Biosciences Price Performance

Shares of Ventyx Biosciences stock opened at $14.00 on Friday. The business has a fifty day simple moving average of $13.23 and a two-hundred day simple moving average of $8.41. Ventyx Biosciences has a 1 year low of $0.78 and a 1 year high of $25.00. The company has a market capitalization of $1.00 billion, a price-to-earnings ratio of -9.33 and a beta of 1.26.

Insider Activity

In other Ventyx Biosciences news, CEO Raju Mohan sold 47,345 shares of the business’s stock in a transaction dated Thursday, December 18th. The shares were sold at an average price of $7.72, for a total value of $365,503.40. Following the completion of the sale, the chief executive officer owned 2,372,863 shares of the company’s stock, valued at $18,318,502.36. The trade was a 1.96% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider John Nuss sold 12,675 shares of the stock in a transaction that occurred on Thursday, December 18th. The stock was sold at an average price of $7.72, for a total transaction of $97,851.00. Following the transaction, the insider owned 489,481 shares in the company, valued at approximately $3,778,793.32. The trade was a 2.52% decrease in their position. The disclosure for this sale is available in the SEC filing. Corporate insiders own 14.49% of the company’s stock.

Institutional Investors Weigh In On Ventyx Biosciences

Hedge funds and other institutional investors have recently made changes to their positions in the business. Mirae Asset Global Investments Co. Ltd. bought a new position in Ventyx Biosciences during the 4th quarter worth $31,000. Hudson Bay Capital Management LP bought a new stake in Ventyx Biosciences during the second quarter worth about $34,000. Engineers Gate Manager LP acquired a new stake in Ventyx Biosciences during the second quarter worth about $42,000. Persistent Asset Partners Ltd acquired a new stake in Ventyx Biosciences during the third quarter worth about $51,000. Finally, Jump Financial LLC bought a new position in Ventyx Biosciences in the 2nd quarter valued at about $53,000. 97.88% of the stock is currently owned by institutional investors and hedge funds.

About Ventyx Biosciences

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome.